A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment With Platinum-Gemcitabine-Nivolumab for Patients With Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)
Latest Information Update: 17 Jun 2025
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- Acronyms REMAIN
Most Recent Events
- 24 Jan 2024 Status changed from not yet recruiting to recruiting.
- 08 Dec 2023 Planned initiation date changed from 14 Dec 2023 to 16 Feb 2024.
- 11 Sep 2023 New trial record